Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.48 |
| ▸ | JAK2 | O60674 | 6/20 | 0.39 |
| ▸ | FLT3 | P36888 | 6/20 | 0.39 |
| ▸ | JAK1 | P23458 | 4/20 | 0.39 |
| ▸ | TYK2 | P29597 | 4/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463634 | 0.87 | EGFR (0.39) | EGFRJAK2FLT3JAK1TYK2 | |
| SCHEMBL416029 | 0.84 | EGFR (0.39) | EGFRJAK2FLT3JAK1TYK2 | |
| SCHEMBL415940 | 0.84 | EGFR (0.39) | EGFRJAK2FLT3JAK1TYK2 | |
| SCHEMBL415933 | 0.82 | EGFR (0.40) | EGFRJAK2FLT3JAK1TYK2 | |
| SCHEMBL415863 | 0.82 | CDK2 (0.49) | EGFRJAK2FLT3JAK1TYK2 | |
| SCHEMBL10258569 | 0.78 | EGFR (0.31) | EGFRFLT3 | |
| SCHEMBL463805 | 0.78 | CCNC (0.41) | EGFRJAK2FLT3JAK1TYK2 | |
| SCHEMBL463815 | 0.77 | MCL1 (0.36) | EGFRFLT3 | |
| SCHEMBL415996 | 0.77 | JAK2 (0.51) | JAK2FLT3JAK1TYK2CCNA2 | |
| SCHEMBL415865 | 0.76 | EGFR (0.41) | EGFRJAK2FLT3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | EGFR 1090/4885JAK2 2835/4885FLT3 2149/4885 |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR1H3, NR1H2, NR0B1 | EGFR 1611/4885JAK2 2841/4885FLT3 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.